Literature DB >> 8641358

p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl.

R Salgia1, M Sattler, E Pisick, J L Li, J D Griffin.   

Abstract

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder caused by the t(9;22) translocation. This translocation creates a unique tyrosine kinase oncogene, bcr/abl, whose product, p210BCR/ABL, is localized to the actin cytoskeleton. One of the major tyrosine phosphoproteins in cells transformed by p210BCR/ABL is the protooncoprotein p120c-Cbl. We have previously shown that p210BCR/ABL induces formation of a multimeric complex of proteins which include p120c-Cbl, phosphotidylinositol-3' kinase, and p210BCR/ABL itself. Here we show that certain focal adhesion proteins are also part of this complex, including paxillin and talin. The sites in paxillin required to bind to p120c-Cbl in this complex have been partially mapped. The interaction of pl20c-Cbl with paxillin is specific, since other focal adhesion proteins, such as p125FAK, vinculin, and alpha-actinin, are not in this complex. The binding of p120c-Cbl to the focal adhesion protein paxillin could contribute to the known adhesive defects of CML cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641358

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  9 in total

1.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.

Authors:  K Okuda; A D'Andrea; R A Etten; J D Griffin
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  BCR/ABL induces multiple abnormalities of cytoskeletal function.

Authors:  R Salgia; J L Li; D S Ewaniuk; W Pear; E Pisick; S A Burky; T Ernst; M Sattler; L B Chen; J D Griffin
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

4.  Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.

Authors:  K R LaMontagne; A J Flint; B R Franza; A M Pandergast; N K Tonks
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

Review 5.  Chronic myeloid leukemia: reminiscences and dreams.

Authors:  Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

6.  Functional mechanisms and roles of adaptor proteins in abl-regulated cytoskeletal actin dynamics.

Authors:  Mizuho Sato; Masahiro Maruoka; Tatsuo Takeya
Journal:  J Signal Transduct       Date:  2012-05-17

7.  Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells.

Authors:  Chia-Hao Chang; Krikor Bijian; Dinghong Qiu; Jie Su; Amine Saad; Michael S Dahabieh; Wilson H Miller; Moulay A Alaoui-Jamali
Journal:  Oncotarget       Date:  2017-05-09

8.  Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.

Authors:  Cleo E Rolle; Yi-Hung Carol Tan; Tanguy Y Seiwert; Sapana Vora; Rajani Kanteti; Rifat Hasina; George B Carey; Mosmi Surati; Ralph R Weichselbaum; Mark W Lingen; Everett E Vokes; Ravi Salgia
Journal:  Oncotarget       Date:  2017-03-21

9.  C3G forms complexes with Bcr-Abl and p38α MAPK at the focal adhesions in chronic myeloid leukemia cells: implication in the regulation of leukemic cell adhesion.

Authors:  Vera Maia; Sara Ortiz-Rivero; María Sanz; Javier Gutierrez-Berzal; Indira Alvarez-Fernández; Sara Gutierrez-Herrero; Jose María de Pereda; Almudena Porras; Carmen Guerrero
Journal:  Cell Commun Signal       Date:  2013-01-23       Impact factor: 5.712

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.